Oral oncology · 2025
The patterns of systemic metastasis in major salivary gland cancer and therapeutic implications.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Subi, Kim Younghac, Kim Hyojun, Kim Eunhye, Woo Sook-Young, Choi Nayeon, Cho Junhun, Oh Dongryul, Ahn Yong-Chan, Park Sehhoon, Ahn Myung-Ju, Jeong Han-Sin
Аннотация
BACKGROUND: This study aimed to investigate the patterns of metastatic spread of salivary gland cancer (SGC) and their therapeutic implications. Patterns of systemic metastasis, post-metastasis survival, and risk factors have not been defined clearly in SGC, and the validity of the concept of oligometastasis in SGC has never been explored.
METHODS: This was a retrospective study of SGC patients with systemic metastasis (N = 199). The primary outcome was post-metastasis disease-specific survival, and multivariable survival analyses for risk factors were performed. The patients were divided into three pathology groups, adenoid cystic carcinomas (ACCs), non-ACC high-grade tumors, and non-ACC intermediate or low-grade tumors.
RESULTS: Median survival was 28.9 months after diagnosis of systemic metastasis. Only 30 % of patients had oligometastasis (≤ 3 metastatic lesions and ≤ 2 involved organs), and polymetastasis was observed in 70 % (33.7 % single organ polymetastasis and 36.2 % multi-organ polymetastasis). Poor patient performance status, shorter metastasis-free interval, non-ACC high-grade tumor, concurrent local disease, and multi-organ polymetastasis were identified as independent risk factors for post-distant metastasis survival. Of note, SGC patients with oligometastasis and single organ polymetastasis showed similar survival outcomes. Systemic chemotherapy did not improve post-metastasis survival of SGC patients significantly. However, HER-2 targeted therapy combined with chemotherapy extended post-metastasis survival in c-erb-B2 expressing tumors.
CONCLUSIONS: Systemic metastasis into multiple organs is a common pattern of SGC metastasis, and significantly affects patient survival. Tumor biology-based therapy should be further sought for improving post-metastasis outcomes of SGC patients.
METHODS: This was a retrospective study of SGC patients with systemic metastasis (N = 199). The primary outcome was post-metastasis disease-specific survival, and multivariable survival analyses for risk factors were performed. The patients were divided into three pathology groups, adenoid cystic carcinomas (ACCs), non-ACC high-grade tumors, and non-ACC intermediate or low-grade tumors.
RESULTS: Median survival was 28.9 months after diagnosis of systemic metastasis. Only 30 % of patients had oligometastasis (≤ 3 metastatic lesions and ≤ 2 involved organs), and polymetastasis was observed in 70 % (33.7 % single organ polymetastasis and 36.2 % multi-organ polymetastasis). Poor patient performance status, shorter metastasis-free interval, non-ACC high-grade tumor, concurrent local disease, and multi-organ polymetastasis were identified as independent risk factors for post-distant metastasis survival. Of note, SGC patients with oligometastasis and single organ polymetastasis showed similar survival outcomes. Systemic chemotherapy did not improve post-metastasis survival of SGC patients significantly. However, HER-2 targeted therapy combined with chemotherapy extended post-metastasis survival in c-erb-B2 expressing tumors.
CONCLUSIONS: Systemic metastasis into multiple organs is a common pattern of SGC metastasis, and significantly affects patient survival. Tumor biology-based therapy should be further sought for improving post-metastasis outcomes of SGC patients.